Mode
Text Size
Log in / Sign up
N/A N=86 Randomized Basic Science

Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD

Chronic Obstructive Pulmonary Disease

Enrolled (actual)
86
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Exercise (Other); Repetitive magnetic stimulation (Other)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Imperial College London
Primary completion
Oct 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Quadriceps Fibre Size of Type IIa Fibres
3885; 4326; 3610

Summary

Background Chronic Obstructive Pulmonary Disease (COPD) patients develop leg weakness and a reduced walking capacity, due to reduced leg muscle oxygen-utilising capacity (OUC). Animal experiments indicate that low muscle levels of Peroxisome Proliferator-Activated Receptors (PPAR) cause the reduced muscle OUC. Aims In COPD patients, investigate whether: 1. reduced muscle PPAR levels cause reduced leg muscle OUC, by investigating a correlation between these in muscle samples (Study 1). 2. training increases muscle PPAR levels in proportion to increases in OUC, as should occur if PPARs control OUC (Study 2). 3. muscle PPAR levels and walking capacity correlate (Study 1 and 2). 3. the new technique of repetitive stimulation of the nerve to the leg with a magnet (rMS) improves muscle OUC (Study 2). Study 1 Leg weakness and walking ability are assessed in 75 patients, then a leg muscle sample is taken to measure PPARs and OUC. Study 2 60 Study 1 patients have either cardiovascular training, rMS, or no training, for 8 weeks, then are re-studied as in Study 1. Importance If reduced PPAR levels correspond with leg weakness, medicines can be developed to target these receptors and treat weakness. If rMS is effective, it can be offered to patients.

Eligibility Criteria

Inclusion Criteria

  • Chronic Obstructive Pulmonary Disease

Exclusion Criteria

  • Cardiac failure
  • Renal failure
  • Liver failure
  • Diabetes mellitus
  • Systemic inflammatory diseases eg Rheumatoid arthritis, SLE
  • Warfarin, coagulation problems
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00737698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search